Hospital del Mar
If you are the contact person for this centre and you wish to make any changes, please contact us.
Professor of Endocrinology in the Department of Medicine and Life Sciences at Pompeu Fabra University, Emeritus Head of the Endocrinology and Nutrition Service at Hospital del Mar in Barcelona and President of the Advisory Council on Diabetes in Catalonia of the Generalitat de Catalunya
Resident doctor in Preventive Medicine and Public Health, Hospital del Mar, Barcelona.
Head of the Department of Medical Oncology at the Hospital del Mar in Barcelona
Head of the Clinical Research Unit in Cancer Immunotherapy at CNIO-HMarBCN
Researcher at the Barcelonabeta Brain Research Center and the Neurology Service of the Hospital del Mar (Barcelona)
Head of the Neurology Service at the Hospital del Mar (Barcelona) and Director of the Neurosciences Programme
A study published in the European Heart Journal shows that people with type 1 and type 2 diabetes have a higher risk of sudden cardiac death than those without these diseases. In addition, their life expectancy is lower. The research analysed data from 6,862 cases of sudden cardiac death in Denmark in 2010, and concluded that the incidence of these deaths is 3.7 times higher in people with type 1 diabetes than in the general population, and 6.5 times higher in people with type 2 diabetes. Those under the age of 50 were at the highest risk.
Over the past 20 years, a class of cancer drugs known as CD40 agonist antibodies has shown great potential, but also limited impact in patients and adverse reactions. In 2018, it was demonstrated that they could be improved to boost their effectiveness and limit serious side effects. A study published in Cancer Cell reports the results of using one of these drugs in a small phase 1 clinical trial: out of 12 patients, all with different types of metastatic cancer, six saw their tumors shrink, including two in whom they disappeared completely.
Researchers at Harvard Medical School have published new findings in Nature on the role of reduced lithium levels in Alzheimer's disease, based on experiments with mice and analysis of brain tissue and blood samples from humans. The team claims to have achieved improvements in memory in mouse models with lithium orotate. They caution that they have not proven that lithium is safe or effective in protecting against neurodegeneration in patients, and that their findings must be confirmed in humans through clinical trials.
EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.
Epstein-Barr virus infection appears to be a necessary condition for developing multiple sclerosis, but the specific mechanisms that cause it in some people are not known. An international study of more than 1,300 people, including 650 patients, has found that elevated production of certain antibodies increases the risk of developing the disease. These antibodies target a specific protein in the virus, but can in turn act in a cross-species manner and damage other similar proteins in the nervous system. The results are published in the journal PNAS.
A team from the University of Iowa (USA) has found a relationship between specific species of microbiota bacteria and the severity of multiple sclerosis. Specifically, a lower ratio between the quantities of Bifidobacterium and Akkermansia was related to the disease and to a worse course of the disease, both in mice and in two cohorts of patients and people without the disease. According to the authors, who publish the results in the journal PNAS, the finding could be used to improve the diagnosis and treatment of multiple sclerosis.
A team of researchers has analysed the evolution of 4,550 people aged 25 to 65 diagnosed with type 2 diabetes who had been studied for 30 years in the UK. They found that those diagnosed before the age of 40 had a risk of dying almost four times higher than in the general population. If diagnosed later, the risk was 1.5 times higher. The authors publish their findings in the journal The Lancet Diabetes & Endocrinology.
A standard chemotherapy drug injures surrounding noncancerous cells, which can awaken dormant cancer cells and promote cancer growth, according to a study published today in the journal PLOS Biology.
Researchers have analysed the presence of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in 72 textile products purchased online in the US and Canada in 2020 and 2021. The results, published in the journal Environmental Science and Technology Letters, show high concentrations in school uniforms and higher concentrations in 100 % cotton as opposed to synthetics.
A review of studies in rodents and humans examines the relationship between exposure to perfluoroalkyl substances (PFAS) and liver damage.